These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 28159408)

  • 21. Assessing BRCA carrier probabilities in extended families.
    Barcenas CH; Hosain GM; Arun B; Zong J; Zhou X; Chen J; Cortada JM; Mills GB; Tomlinson GE; Miller AR; Strong LC; Amos CI
    J Clin Oncol; 2006 Jan; 24(3):354-60. PubMed ID: 16421416
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
    Fischer C; Kuchenbäcker K; Engel C; Zachariae S; Rhiem K; Meindl A; Rahner N; Dikow N; Plendl H; Debatin I; Grimm T; Gadzicki D; Flöttmann R; Horvath J; Schröck E; Stock F; Schäfer D; Schwaab I; Kartsonaki C; Mavaddat N; Schlegelberger B; Antoniou AC; Schmutzler R;
    J Med Genet; 2013 Jun; 50(6):360-7. PubMed ID: 23564750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Selecting a BRCA risk assessment model for use in a familial cancer clinic.
    Panchal SM; Ennis M; Canon S; Bordeleau LJ
    BMC Med Genet; 2008 Dec; 9():116. PubMed ID: 19102775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Performance of BRCA1/2 mutation prediction models in Asian Americans.
    Kurian AW; Gong GD; Chun NM; Mills MA; Staton AD; Kingham KE; Crawford BB; Lee R; Chan S; Donlon SS; Ridge Y; Panabaker K; West DW; Whittemore AS; Ford JM
    J Clin Oncol; 2008 Oct; 26(29):4752-8. PubMed ID: 18779604
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictability of BRCA1/2 mutation status in patients with ovarian cancer: How to select women for genetic testing in middle-income countries.
    Teixeira N; Maistro S; Del Pilar Estevez Diz M; Mourits MJ; Oosterwijk JC; Folgueira MAK; de Bock GH
    Maturitas; 2017 Nov; 105():113-118. PubMed ID: 28619461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Comparison of hereditary breast and ovarian cancer syndrome and sporadic ovarian cancer in ovarian cancer BRCA mutations].
    Duan RR; Sun LX; Zhao HW
    Zhonghua Fu Chan Ke Za Zhi; 2021 Nov; 56(11):788-795. PubMed ID: 34823292
    [No Abstract]   [Full Text] [Related]  

  • 27. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.
    Vogel KJ; Atchley DP; Erlichman J; Broglio KR; Ready KJ; Valero V; Amos CI; Hortobagyi GN; Lu KH; Arun B
    J Clin Oncol; 2007 Oct; 25(29):4635-41. PubMed ID: 17925560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group.
    Alsop K; Fereday S; Meldrum C; deFazio A; Emmanuel C; George J; Dobrovic A; Birrer MJ; Webb PM; Stewart C; Friedlander M; Fox S; Bowtell D; Mitchell G
    J Clin Oncol; 2012 Jul; 30(21):2654-63. PubMed ID: 22711857
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimate of the penetrance of BRCA mutation and the COS software for the assessment of BRCA mutation probability.
    Berrino J; Berrino F; Francisci S; Peissel B; Azzollini J; Pensotti V; Radice P; Pasanisi P; Manoukian S
    Fam Cancer; 2015 Mar; 14(1):117-28. PubMed ID: 25373702
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ.
    Bayraktar S; Elsayegh N; Gutierrez Barrera AM; Lin H; Kuerer H; Tasbas T; Muse KI; Ready K; Litton J; Meric-Bernstam F; Hortobagyi GN; Albarracin CT; Arun B
    Cancer; 2012 Mar; 118(6):1515-22. PubMed ID: 22009639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and Spectrum of
    Foglietta J; Ludovini V; Bianconi F; Pistola L; Reda MS; Al-Refaie A; Tofanetti FR; Mosconi A; Minenza E; Anastasi P; Molica C; Stracci F; Roila F
    Genes (Basel); 2020 Aug; 11(8):. PubMed ID: 32806537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recurrent mutation testing of BRCA1 and BRCA2 in Asian breast cancer patients identify carriers in those with presumed low risk by family history.
    Kang PC; Phuah SY; Sivanandan K; Kang IN; Thirthagiri E; Liu JJ; Hassan N; Yoon SY; Thong MK; Hui M; Hartman M; Yip CH; Mohd Taib NA; Teo SH
    Breast Cancer Res Treat; 2014 Apr; 144(3):635-42. PubMed ID: 24578176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection.
    van Harssel JJ; van Roozendaal CE; Detisch Y; Brandão RD; Paulussen AD; Zeegers M; Blok MJ; Gómez García EB
    Fam Cancer; 2010 Jun; 9(2):193-201. PubMed ID: 19949876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of mathematical models for breast cancer risk assessment in routine clinical use.
    Fasching PA; Bani MR; Nestle-Krämling C; Goecke TO; Niederacher D; Beckmann MW; Lux MP
    Eur J Cancer Prev; 2007 Jun; 16(3):216-24. PubMed ID: 17415092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients.
    Singer CF; Tan YY; Muhr D; Rappaport C; Gschwantler-Kaulich D; Grimm C; Polterauer S; Pfeiler G; Berger A; Tea MM
    Cancer Med; 2019 Apr; 8(4):1875-1881. PubMed ID: 30821131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients.
    Rao NY; Hu Z; Li WF; Huang J; Ma ZL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 Feb; 113(3):467-77. PubMed ID: 18343994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States.
    Huo D; Senie RT; Daly M; Buys SS; Cummings S; Ogutha J; Hope K; Olopade OI
    J Clin Oncol; 2009 Mar; 27(8):1184-90. PubMed ID: 19188678
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accuracy of Risk Prediction Models for Breast Cancer and
    Kenan ES; Friger M; Shochat-Bigon D; Schayek H; Bernstein-Molho R; Friedman E
    Anticancer Res; 2018 Aug; 38(8):4557-4563. PubMed ID: 30061222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of novel mutations of ovarian cancer-related genes from RNA-sequencing data for Japanese epithelial ovarian cancer patients.
    Nagasawa S; Ikeda K; Horie-Inoue K; Sato S; Takeda S; Hasegawa K; Inoue S
    Endocr J; 2020 Feb; 67(2):219-229. PubMed ID: 31748433
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.